WitrynaEUROPEAN LUNG CANCER CONFERENCE 2024 Reck et al. IMpower150 in EGFR-mt pts After failure of first -line TKIs, patients with EGFR mutations have limited treatment options 1-3 Continuation of TKI therapy with chemotherapy is generally associated with worse survival outcomes than treatment with later- generation TKIs 1,2 Most patients … WitrynaEfficacy was evaluated in IMpower130 (NCT02367781), a multicenter, randomized (2:1), open-label trial in patients with stage IV non-squamous NSCLC who had received no prior chemotherapy for ...
ESMO Virtual Congress 2024 OncologyPRO
Witryna§ IMpower130 (NCT02367781) was a multicentre, randomised, open-label, phase 3 study that assessed atezo + CnP, vs CnP, in chemotherapy-naive stage IV non … Witryna19 sty 2024 · Phase 3 trials evaluating the efficacy of atezolizumab combined with carboplatin and nab-paclitaxel (IMpower130) ... At the time of the OS final analysis, the updated median PFS in the Japanese subpopulation was 13.3 (95% CI, 9.5-17.4) mo with APP compared with 4.5 (95% CI, 4.1-6.7) mo in the PP patients (stratified HR, ... how to identify good rolls in armor destiny 2
IMpower132: Atezolizumab plus platinum‐based chemotherapy vs ...
WitrynaAt the final IMpower150 OS analysis, ACP had numerical, but not statistically significant, OS improvement versus BCP. Updated data with an additional 20 months of follow … WitrynaThe IMpower130 trial confirmed that a combination of anti PD-1 plus chemotherapy could be an appropriate strategy for patients affected by advanced NSCLC, without … WitrynaIntroduction: IMpower110 previously revealed significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR- and ALK-negative (wild type [WT]) metastatic NSCLC with high programmed death-ligand 1 (PD-L1) expression (≥50% on tumor cells [TCs] or ≥10% on tumor-infiltrating immune cells … how to identify gold plated jewelry